```html

Idiopathic Thrombocytopenic Purpura (ITP)

What is Idiopathic Thrombocytopenic Purpura?

Idiopathic thrombocytopenic purpura (ITP), also called immune thrombocytopenia, is an acquired blood disorder characterized by a low platelet count (thrombocytopenia) caused by an abnormal immune response that destroys platelets or impairs their production. Platelets are tiny cell fragments that help blood clot; when their numbers drop below 150,000 per microliter, bruising, bleeding, and petechiae (tiny red spots) can develop. The term “idiopathic” means the exact cause is unknown, but the condition is now understood to be immune‑mediated rather than truly mysterious.

ITP can affect anyone, but it is most common in children (often after a viral infection) and in adults, especially women aged 20‑40 years. The disease may be acute (lasting weeks to months) or chronic (persisting for > 6 months). In many cases, patients have few symptoms and are diagnosed incidentally during routine blood work.

Common Causes

Although “idiopathic” suggests an unknown cause, several conditions and triggers have been linked to the development of immune‑mediated thrombocytopenia. The following list includes the most frequently reported associations:

• Viral infections – e.g., hepatitis C, HIV, Epstein‑Barr virus, and recent childhood illnesses such as measles or rubella.
• Helicobacter pylori infection – eradication of the bacteria can improve platelet counts in some adults.
• Medications – quinine, sulfonamides, penicillins, non‑steroidal anti‑inflammatory drugs (NSAIDs), and heparin can trigger immune destruction of platelets.
• Autoimmune diseases – systemic lupus erythematosus (SLE), rheumatoid arthritis, and antiphospholipid syndrome.
• Vaccinations – rare cases have been reported after influenza or MMR vaccines; the benefits of vaccination far outweigh the risk.
• Pregnancy – gestational ITP can appear during the second or third trimester and may resolve after delivery.
• Underlying lymphoproliferative disorders – chronic lymphocytic leukemia (CLL) and lymphoma can produce antibodies that attack platelets.
• Thyroid disease – both hyper‑ and hypothyroidism have been associated with ITP.
• Genetic predisposition – certain HLA haplotypes (e.g., HLA‑DR4) increase susceptibility.
• Idiopathic – in up to 30 % of adults no trigger is identified despite thorough evaluation.

Associated Symptoms

Symptoms of ITP arise from bleeding caused by low platelet numbers. The severity varies with platelet count:

• Petechiae – tiny red or purple spots on the skin, especially on the legs, arms, and mucous membranes.
• Purpura – larger bruises that may appear spontaneously or after minimal trauma.
• Epistaxis (nosebleeds) and gingival bleeding (bleeding gums).
• Hematuria (blood in urine) or hemoptysis (coughing up blood) in severe cases.
• Menorrhagia – heavy menstrual bleeding in women of reproductive age.
• Fatigue – often due to anemia if bleeding is chronic.
• Blood in stools or rectal bleeding – indicates gastrointestinal involvement.
• Intracranial hemorrhage – rare but life‑threatening; patients may develop headache, confusion, or seizures.

When to See a Doctor

Although mild bruising may be harmless, any of the following signs warrant prompt medical evaluation:

• Unexplained bruises or purpura, especially on the torso or limbs.
• Bleeding that won’t stop after 10‑15 minutes of pressure (e.g., nosebleeds).
• Blood in urine, stool, or vomit.
• Persistent heavy menstrual periods.
• Sudden, severe headache, visual changes, weakness, or loss of balance (possible brain bleed).
• Easy bleeding after minor cuts or dental work.
• Sudden drop in platelet count on routine labs (< 30,000/µL) even without symptoms.

Diagnosis

Diagnosing ITP is largely one of exclusion—ruling out other causes of thrombocytopenia. The typical work‑up includes:

1. Medical History & Physical Exam

• Recent infections, medication use, vaccination history, pregnancy status, and family history of autoimmune disease.
• Examination for petechiae, purpura, lymphadenopathy, splenomegaly, or signs of systemic illness.

2. Laboratory Tests

• Complete blood count (CBC) with peripheral smear – low platelet count with normal white and red cells; smear shows large platelets.
• Coagulation profile (PT/INR, aPTT) – usually normal, helping differentiate from clotting factor deficiencies.
• Anti‑platelet antibody testing – not routinely required because of low sensitivity, but may be used in research settings.
• Hepatitis C, HIV, and H. pylori screening – identifies treatable underlying causes.
• Thyroid function tests – to uncover autoimmune thyroid disease.

3. Bone Marrow Examination

Reserved for atypical cases (e.g., patients > 60 years with additional cytopenias) to rule out marrow infiltration or leukemia.

4. Imaging

Ultrasound or CT scan may be ordered if splenomegaly or an abdominal mass is suspected.

Treatment Options

Therapy is individualized based on platelet count, bleeding risk, age, comorbidities, and patient preferences. The goal is to raise platelets enough to prevent serious bleeding while minimizing drug toxicity.

First‑Line (Initial) Therapies

• Corticosteroids (prednisone 0.5–1 mg/kg/day or dexamethasone 40 mg daily for 4 days) – quickly increase platelet production by dampening the immune response.
• Intravenous immunoglobulin (IVIG) – 1 g/kg daily for 1–2 days; useful for rapid rise in platelets before surgery or in severe bleeding.
• Anti‑D immunoglobulin (Rh‑compatible) – for Rh‑positive, non‑splenectomized patients; works by saturating macrophage Fc receptors.

Second‑Line (Maintenance) Therapies

• Rituximab – anti‑CD20 monoclonal antibody; often given weekly for 4 weeks; effective in many chronic cases.
• Thrombopoietin receptor agonists (TPO‑RAs) – eltrombopag (oral) or romiplostim (subcutaneous); stimulate platelet production. FDA‑approved for chronic ITP.
• Mycophenolate mofetil or Azathioprine – immunosuppressants used when steroids are contraindicated or refractory.
• Splenectomy – surgical removal of the spleen; provides durable remission in 60‑70 % of adults but carries lifelong infection risk. Considered after failure of medical therapy.

Supportive & Home Measures

• Avoid medications that impair platelet function (aspirin, NSAIDs, clopidogrel).
• Use soft toothbrushes and avoid flossing aggressively.
• Apply gentle pressure to cuts; use hemostatic gauze if bleeding persists.
• Wear protective gear during contact sports or high‑impact activities.
• Maintain adequate folic acid and vitamin B12 intake to support overall bone‑marrow health.

Prevention Tips

True primary prevention of ITP is not possible because many cases are idiopathic. However, secondary prevention—reducing triggers and complications—can be achieved through the following actions:

• Stay up‑to‑date with vaccinations; discuss any concerns with your provider.
• Avoid unnecessary or high‑dose aspirin/NSAIDs; use acetaminophen for pain when appropriate.
• If you have a known autoimmune condition, adhere to treatment plans to keep disease activity low.
• Screen for and treat chronic infections such as H. pylori, hepatitis C, and HIV promptly.
• Women of child‑bearing age should have platelet counts checked before pregnancy; manage ITP under obstetric‑hematology care.
• Regular follow‑up labs (every 3‑6 months) if you have chronic ITP, even when asymptomatic.

Emergency Warning Signs

Key Take‑aways

Idiopathic thrombocytopenic purpura is an immune‑mediated condition that leads to low platelets and a bleeding tendency. While many patients experience mild symptoms, others may develop serious hemorrhage. Prompt diagnosis, appropriate treatment (often starting with steroids or IVIG), and regular monitoring help most people maintain a normal lifestyle. Always consult a healthcare professional if you notice new bruises, bleeding, or any of the red‑flag symptoms listed above.

References:

• Mayo Clinic. “Immune thrombocytopenic purpura (ITP).” 2023.
• National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). “ITP Overview.” 2022.
• Cleveland Clinic. “Thrombocytopenia (Low Platelet Count).” Updated 2023.
• World Health Organization. “Guidelines for the Management of ITP.” 2021.
• Humblet H et al. “Treatment of adult ITP with rituximab.” *Blood Advances*, 2022.
• Provan D, Stasi R. “Management of ITP in adults.” *New England Journal of Medicine*, 2020.

```